Denis DryginSVP, Development at Haya TherapeuticsSpeaker
Profile
Dr. Denis Drygin is a seasoned biologist and pharmacologist with over 20 years of expertise in discovering and developing RNA-targeting therapeutics. Throughout his career, he has led or supervised the development of six drug candidates into clinical trials, including the oligonucleotide Farabursen (acquired by Novartis). Dr. Drygin has held key leadership roles at Regulus Therapeutics, Cylene Pharmaceuticals, and Nosis Biosciences, and was a co-founder of Pimera Therapeutics. He began his RNA career with post-doctoral training at Ionis Pharmaceuticals, focusing on ASO pharmacology and toxicology. As SVP of Development at HAYA Therapeutics, Denis oversees R&D strategy, driving the pipeline from candidate selection through IND.
Agenda Sessions
From Discovery toward the Clinic: Translational Development of an ASO Targeting a Cardiac Myofibroblast-specific LncRNA
, 9:30amView Session